Synonyms: CDP-7657 | CDP7657 | DZP
Compound class:
Antibody
Comment: Dapirolizumab pegol (CDP7657) is a pegylated monovalent Fab' immunomodulator that targets CD40 ligand [1]. It was developed by UCB Pharma. Removal of the Fc domain prevented the increased risk of thrombotic events observed with an intact mAb.
|
Immunopharmacology Comments |
Dapirolizumab pegol blocks the stimulatory CD40/CD40 ligand immune checkpoint. It is being investigated for potential to subdue abnormal activation of the immune system in autoimmune disease. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Clinical candidate for the treatment of SLE. |